ArticleInternational journal of clinical and experimental pathology2017
Concordance of immunohistochemistry and fluorescence
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Validation and Prospective Testing of a High-Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides.Laboratory investigation; a journal of technical methods and pathology · 2025Article
- Article
- Clinicopathological Characteristics of Breast Cancer Patients with Equivocal Immunohistochemistry: A Prevalence-Based Statistical Analysis.Iranian journal of pathology · 2025Article
- Clinical characteristics and prognosis of breast cancer patients with ovarian metastases.Frontiers in oncology · 2025Article
- Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the concordance rate between Immunohistochemistry (IHC) and fluorescence
methodsBetween January 2010 and June 2016, paraffin-embedded specimens form 1032 cases of breast cancer at the Tumor Hospital Affiliated to the Xinjiang Medical University were examined for HER2 status via both IHC and FISH using standard methodologies. The concordance between the two methods was then statistically evaluated.
resultsThe IHC 0, 1+ and 3+ cases had a high concordance rate of 100%, 90.6% and 91.7%, respectively. The IHC 2+ had a low concordance rate (64.4%). 78.6% (293/373) HER2 positive specimens (2+ and 3+) showed HER2 gene amplification and 95.1% (627/659) HER negative cases (0 and 1+) were HER2 non-amplified, yielding a kappa score of 0.7581 (
conclusionIHC can be used as an initial screening test of HER2 status for both populations in Xinjiang province. However, for cases with a HER2 IHC 2+ result, a FISH test is required for confirmation.
Indexed as
Identifiers
31966383PMC6965800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.